BiolineRx Poised for Record Jump After Deal With Genoscience
BioLineRx Ltd. (BLRX) was headed for the biggest surge on record after the Israeli company that develops therapeutic pharmaceutical drugs signed a deal with France’s Genoscience to develop and commercialize a treatment.
The shares surged 33 percent, the most on a closing basis since February 2007 when Bloomberg started tracking them, to 1.598 shekels at 3:57 p.m. in Tel Aviv.
BioLineRx signed an “exclusive license agreement” with Genoscience for its BL-8020 oral treatment for Hepatitis C, it said in a filing with the Tel Aviv Stock Exchange.
To contact the reporter on this story: Shoshanna Solomon in Tel Aviv at email@example.com
To contact the editor responsible for this story: Claudia Maedler at firstname.lastname@example.org
Bloomberg reserves the right to edit or remove comments but is under no obligation to do so, or to explain individual moderation decisions.